Chronic convection-enhanced intratumoural delivery of chemotherapy for glioblastoma

Mené aux Etats-Unis entre 2018 et 2019 sur 5 patients atteints d'un glioblastome solitaire récidivant (durée médiane de suivi : 12 mois), cet essai de phase IB évalue la toxicité d'une administration intratumorale chronique améliorée par convection de topotécan

Résumé en anglais

In The Lancet Oncology, Eleonora F Spinazzi and colleagues present a first-in-human study of chronic convection-enhanced delivery (CED) of chemotherapy to five patients with recurrent glioblastoma.1 CED involves stereotactic placement of catheter(s) into a tumour, followed by connecting the catheter(s) to pumps to allow intratumoural drug distribution by bulk flow via continuous, low-grade, positive-pressure microinfusion. The rationale for CED of chemotherapies in glioblastoma is the ability of this technique to deliver high intratumoural drug concentrations throughout the tumour, bypass the blood–brain barrier, and avoid toxic effects from systemic drug administration.